Aldosterone may contribute to cardiovascular morbidity and mortality among patients receiving maintenance dialysis, but whether mineralocorticoid receptor antagonists improve outcomes in this population is uncertain. With the ACHIEVE trial (NCT030203... [1352 chars].. reed more
